Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

146.82 +0.08 (+0.05%)
Streaming Delayed Price Updated: 9:58 AM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
From Gilead Sciences, Inc.
Via Business Wire
Global Drugmakers Earmark Billions to Ramp Up Their US Footprint
Via Investor Brand Network
Topics World Trade
News headline image
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
From Gilead Sciences, Inc.
Via Business Wire
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
Via Investor Brand Network
News headline image
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
From BioMedWire
Via GlobeNewswire
News headline image
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
News headline image
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
From Gilead Sciences, Inc.
Via Business Wire
News headline image
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
From Merck & Co., Inc.
Via Business Wire
News headline image
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Prices $3 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces First Quarter Financial Results
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.